Korean J Urol.  2012 Sep;53(9):593-597. 10.4111/kju.2012.53.9.593.

Prostate Cancer in Patients with Metabolic Syndrome Is Associated with Low Grade Gleason Score When Diagnosed on Biopsy

• Jeon KP
• Jeong TY
• Lee SY
• Hwang SW
• Shin JH
• Kim DS

• KMID: 2061696
• DOI: http://doi.org/10.4111/kju.2012.53.9.593

Abstract

PURPOSE
Studies on the relationship of metabolic syndrome (MS) and prostate cancer are controversial. We evaluated the association between MS and prostate cancer characteristics in patients who underwent transrectal ultrasound-guided prostate biopsy.
MATERIALS AND METHODS
From October 2003 to May 2011, patients with a prostate-specific antigen (PSA) value> or =4 ng/ml or abnormal digital rectal examination (DRE) result underwent transrectal ultrasound-guided prostate biopsy. MS was diagnosed according to the Adult Treatment Panel III. Clinicopathologic factors including PSA, DRE, prostate volume, age, waist circumference, body mass index (BMI), lipid profiles, fasting blood sugar level, and MS were considered for analysis.
RESULTS
Three hundred fifty-four patients were enrolled (mean age, 68.86+/-8.95 years; mean PSA, 13.97+/-20.42 ng/ml). Seventy-five patients (21.2%) had MS and 90 patients (25.4%) were diagnosed as having prostate cancer, including 27 (30%) with MS and 63 (70%) without MS. Total PSA value and prostate volume were significant predictors for prostate cancer. However, MS and BMI were not significantly related to increased cancer risk. Prostate cancer patients with MS had significantly lower Gleason scores (average, 6.63+/-1.92) than did prostate cancer patients without MS (average, 7.54+/-1.71; p=0.029).
CONCLUSIONS
Presence of MS was associated with a significantly decreased risk of high-grade prostate cancer. A larger, prospective, multicenter investigation is mandatory to clarify the relationship between MS and prostate cancer.

Keyword

Biopsy; Metabolic syndrome; Prostatic neoplasms

MeSH Terms

Adult
Biopsy
Blood Glucose
Body Mass Index
Digital Rectal Examination
Fasting
Humans
Neoplasm Grading
Prostate
Prostate-Specific Antigen
Prostatic Neoplasms
Waist Circumference
Blood Glucose
Prostate-Specific Antigen

Reference

1. Ministry of Health and Welfare. Korea Central Cancer Registry. National Cancer Center. Annual report of cancer statistics in Korea in 2009. 2011. Goyang: Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center.

2. Kirby MG, Wagg A, Cardozo L, Chapple C, Castro-Diaz D, de Ridder D, et al. Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn. 2010. 29:1360–1364.

3. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011. 9:48.

4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003. 348:1625–1638.

5. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002. 11:1531–1543.

6. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004. 13:1646–1650.

7. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev. 2002. 3:303–308.

8. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006. 164:1094–1102.

9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002. 106:3143–3421.

10. Chung HW, Kim DJ, Jin HD, Choi SH, Ahn CW, Cha BS, et al. Prevalence of metabolic syndrome according to the new criteria for obesity. J Korean Diabetes Assoc. 2002. 26:431–442.

11. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004. 266:37–56.

12. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. 363:1346–1353.

13. Lee SE, Hong SK, Park HZ, Chang JS, Yoon CY, Byun SS, et al. Higher body mass index is associated with lower risk of prostate cancer detection via multi (≥12)-core prostate biopsy in Korean men. Urology. 2010. 76:1063–1066.

14. Freedland SJ, Terris MK, Platz EA, Presti JC Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology. 2005. 66:108–113.

15. de Santana IA, Moura GS, Vieira NF, Cipolotti R. Metabolic syndrome in patients with prostate cancer. Sao Paulo Med J. 2008. 126:274–278.

16. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control. 2006. 17:5–9.

17. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004. 13:47–55.

18. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate. 2011. 02. [Epub]. http://dx.doi.org/10.1002/pros.21364.

19. Han BK, Choi WS, Yu JH, Han JH, Chang IH, Jeong SJ, et al. The characteristics of prostate cancer with metabolic syndrome in Korean men. Korean J Urol. 2007. 48:585–591.

20. Moreira DM, Anderson T, Gerber L, Thomas JA, Banez LL, McKeever MG, et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control. 2011. 22:977–983.

21. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000. 21:215–244.

22. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003. 195:127–137.

23. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998. 279:563–566.

24. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012. 61:560–570.

25. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005. 14:1262–1269.